In this research, we found that ERRs are significantly associated with MSI and TMB across various cancer types, revealing the feasibility of modulating the activity of ESRRs to regulate the sensitivity of tumors to anti-PD-1/PD-L1 therapies. This evidence concerns the gene CD274 and cancer.